PMID- 27185284
OWN - NLM
STAT- MEDLINE
DCOM- 20171030
LR  - 20171030
IS  - 1749-4486 (Electronic)
IS  - 1749-4478 (Linking)
VI  - 42
IP  - 1
DP  - 2017 Feb
TI  - Outcomes of intensity-modulated radiotherapy as primary treatment for
      oropharyngeal squamous cell carcinoma - a European singleinstitution analysis.
PG  - 115-122
LID - 10.1111/coa.12674 [doi]
AB  - OBJECTIVES: To analyse survival and toxicity outcomes in patients treated with
      primary intensity-modulated radiotherapy (IMRT) for oropharyngeal squamous cell
      carcinoma (OPSCC) in the era of routine human papilloma virus (HPV) testing.
      DESIGN: Single-institution case series. SETTING: Tertiary Head and Neck Cancer
      Unit. PARTICIPANTS: A total of 186 patients received IMRT (+/- chemotherapy) for 
      radical primary treatment of OPSCC between March 2010 and December 2013. HPV
      status was available for 88% of cases. Median radiation dose was 65 Gy in 30
      daily fractions. 90% of stage III/IV patients received concurrent chemotherapy or
      cetuximab. MAIN OUTCOME MEASURES: Overall, disease-free and disease-specific
      survival; rates of late xerostomia and dysphagia. RESULTS: A total of 177
      patients completed treatment (Stage I/II: 23; Stage III/IV: 154), with median
      follow-up of 26 months. Estimated 3-year overall survival (OS), disease-free
      survival (DFS) and disease-specific survival (DSS) rates were 77.2% (70.5-83.9), 
      72.3% (65.4-79.2) and 80.2% (74.1-86.3). Estimated 3-year OS, DFS and DSS for
      HPV-positive patients were 90.9% (85.2-96.6), 87.9% (81.4-94.4) and 91.8%
      (86.3-97.3). A previously identified risk stratification method was validated,
      showing improved OS for low-risk over high-risk patients (HR 0.09, P < 0.001).
      The 2-year feeding tube retention rate was 6%, and 2-year grade >/=2 xerostomia
      rate was 38% (23% if mean contralateral parotid dose <24 Gy). CONCLUSIONS:
      Outcomes with IMRT are favourable, particularly in the HPV-positive patient
      group. This data further supports the use of a previously described
      prognostication model that can be used to select patients for
      escalation/de-escalation clinical trials.
CI  - (c) 2016 John Wiley & Sons Ltd.
FAU - Bird, T
AU  - Bird T
AD  - Department of Clinical Oncology, Guy's & St Thomas' NHS Foundation Trust, London,
      UK.
FAU - De Felice, F
AU  - De Felice F
AD  - Department of Clinical Oncology, Guy's & St Thomas' NHS Foundation Trust, London,
      UK.
FAU - Michaelidou, A
AU  - Michaelidou A
AD  - Department of Clinical Oncology, Guy's & St Thomas' NHS Foundation Trust, London,
      UK.
FAU - Thavaraj, S
AU  - Thavaraj S
AD  - Department of Pathology, Guy's & St Thomas' NHS Foundation Trust, London, UK.
FAU - Jeannon, J-P
AU  - Jeannon JP
AD  - Department of Head & Neck Surgery, Guy's & St Thomas' NHS Foundation Trust,
      London, UK.
FAU - Lyons, A
AU  - Lyons A
AD  - Department of Head & Neck Surgery, Guy's & St Thomas' NHS Foundation Trust,
      London, UK.
FAU - Oakley, R
AU  - Oakley R
AD  - Department of Head & Neck Surgery, Guy's & St Thomas' NHS Foundation Trust,
      London, UK.
FAU - Simo, R
AU  - Simo R
AD  - Department of Head & Neck Surgery, Guy's & St Thomas' NHS Foundation Trust,
      London, UK.
FAU - Lei, M
AU  - Lei M
AD  - Department of Clinical Oncology, Guy's & St Thomas' NHS Foundation Trust, London,
      UK.
FAU - Guerrero Urbano, T
AU  - Guerrero Urbano T
AD  - Department of Clinical Oncology, Guy's & St Thomas' NHS Foundation Trust, London,
      UK.
LA  - eng
PT  - Journal Article
DEP - 20160619
PL  - England
TA  - Clin Otolaryngol
JT  - Clinical otolaryngology : official journal of ENT-UK ; official journal of
      Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
JID - 101247023
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/mortality/*therapy
MH  - Chemotherapy, Adjuvant
MH  - Deglutition Disorders/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oropharyngeal Neoplasms/mortality/*therapy
MH  - Radiotherapy, Intensity-Modulated/*adverse effects
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
MH  - United Kingdom
MH  - Xerostomia/*epidemiology
EDAT- 2016/05/18 06:00
MHDA- 2017/10/31 06:00
CRDT- 2016/05/18 06:00
PHST- 2016/05/11 00:00 [accepted]
PHST- 2016/05/18 06:00 [pubmed]
PHST- 2017/10/31 06:00 [medline]
PHST- 2016/05/18 06:00 [entrez]
AID - 10.1111/coa.12674 [doi]
PST - ppublish
SO  - Clin Otolaryngol. 2017 Feb;42(1):115-122. doi: 10.1111/coa.12674. Epub 2016 Jun
      19.